Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Use and pharmaceutical expenditures on antihypertensive and antihyperlipidemic drugs.

More »

Table 1 Expand

Table 2.

Use and spending on antihypertensive and antihyperlipidemic drugs by age.

More »

Table 2 Expand

Table 3.

Use and pharmaceutical expenditures for antihypertensive drugs by therapeutic class.

More »

Table 3 Expand

Table 4.

Use and spending on antihypertensive and antihyperlipidemic drugs by ATC class and single versus combination.

More »

Table 4 Expand

Fig 1.

Drug spending on antihypertensive and antihyperlipidemic drugs by ingredients.

Note. C02CA04: doxazosin, C03AA03: hydrochlorothiazide, C03CA01: furosemide, C03DA01: spironolactone, C07AG02: carvedilol, C07AB12: nebivolol, C07AB07: bisoprolol, C07AB03: atenolol, C07AA05: betaxolol, C08CA01: amlodipine, C08CA05: nifedipine, C08DB01: diltiazem, C08CA13: lercanidipine, C08CA02: felodipine, C08CA14: cilnidipine, C09DB04: telmisartan+amlodipine, C09DB01: valsartan+amlodipine, C09DB02: olmesartan medoxomil+amlodipine, C09DB06: losartan+amlodipine, C09DA01: losartan+diuretics, C09CA01: losartan, C09CA06: candesartan, C09DX03: olmesartan, edoxomil, amlodipine+hydrochlorothiazide, C09CA03: valsartan, C09CA07: telmisartan, C09DA03: valsartan+diuretics, C09DA06: candesartan+diuretics, C09DA07: telmisartan+diuretics, C09CA08: olmesartan medoxomil+diuretics, C09CA10: fimasartan, C09DB07: candesartan+amlodipine, C09DA08: olmesartan medoxomil+diuretics, C09CA04: irbesartan, C10AA05: atorvastatin, C10AA07: rosuvastatin, C10BA06: rosuvastatin+ezetimibe, C10AA08: pitavastatin, C10AB05: fenofibrate, C10BA05:atorvastatin+ezetimibe, C10BX03: atorvastatin+amlodipine, C10BA02: simvastatin+ezetimibe, C10BA03: pravastatin+fenofibrate, C10AB11: choline fenofibrate, C10AA01: simvastatin, C10AA03: pravastatin, C10BX10: rosuvastatin+valsartan.

More »

Fig 1 Expand